Protein-Based Drug Delivery in Brain Tumor Therapy

被引:3
作者
Hwang, Hae Hyun [1 ,2 ,3 ]
Lee, Dong Yun [1 ,2 ,3 ]
机构
[1] Hanyang Univ, Coll Engn, Dept Bioengn, Seoul, South Korea
[2] Hanyang Univ, BK21 PLUS Future Biopharmaceut Human Resource Tra, Seoul, South Korea
[3] Hanyang Univ, Inst Nano Sci & Technol INST, Seoul, South Korea
来源
BIOINSPIRED BIOMATERIALS: ADVANCES IN TISSUE ENGINEERING AND REGENERATIVE MEDICINE | 2020年 / 1249卷
基金
新加坡国家研究基金会;
关键词
Brain tumor; Drug delivery; Oral administration of protein-based drug; Drug stability; GLYCOPROTEIN INHIBITOR HM-30181; BLOOD-BRAIN; P-GLYCOPROTEIN; IN-VITRO; ALBUMIN NANOPARTICLES; BARRIER PERMEABILITY; ORAL BIOAVAILABILITY; PLGA NANOPARTICLES; PACLITAXEL TAXOL; TRANSFERRIN;
D O I
10.1007/978-981-15-3258-0_13
中图分类号
Q813 [细胞工程];
学科分类号
摘要
Despite the use of active surgeries, radiotherapy, and chemotherapy in clinical practice, brain tumors are still a difficult health problem due to their rapid development and poor prognosis. To treat brain tumors, various nanoparticles can be used to target effective physiological conditions based on continuously changing vascular characteristics and microenvironments to promote effective brain tumor-targeting drug delivery. In addition, a brain tumor-targeting drug delivery system that increases drug accumulation in the brain tumor area and reduces toxicity in the normal brain and peripheral tissues is needed. However, the blood-brain barrier is a big obstacle for drug delivery to the brain. In this chapter, we provide a broad overview of brain drug delivery and current strategies over the last few years. In addition, several questions have been reconsidered, such as whether nanoparticles believed to be delivered to the brain can pass through the blood-brain barrier, whether the drug is delivered to the target site, and what brain tumor treatment is possible.
引用
收藏
页码:203 / 221
页数:19
相关论文
共 138 条
[1]   In vitro and in vivo effect of human lactoferrin on glioblastoma growth [J].
Arcella, Antonietta ;
Oliva, Maria Antonietta ;
Staffieri, Sabrina ;
Alberti, Silvia ;
Grillea, Giovanni ;
Madonna, Michele ;
Bartolo, Marcello ;
Pavone, Luigi ;
Giangaspero, Felice ;
Cantore, Giampaolo ;
Frati, Alessandro .
JOURNAL OF NEUROSURGERY, 2015, 123 (04) :1026-1035
[2]   The blood-brain barrier: an overview - Structure, regulation, and clinical implications [J].
Ballabh, P ;
Braun, A ;
Nedergaard, M .
NEUROBIOLOGY OF DISEASE, 2004, 16 (01) :1-13
[3]   From blood-brain barrier to blood-brain interface: new opportunities for CNS drug delivery [J].
Banks, William A. .
NATURE REVIEWS DRUG DISCOVERY, 2016, 15 (04) :275-+
[4]  
Barrett G.C., 1998, Amino Acids and Peptides
[5]   THE MULTIDRUG-RESISTANCE GENE MDR1 IS EXPRESSED IN HUMAN GLIAL TUMORS [J].
BECKER, I ;
BECKER, KF ;
MEYERMANN, R ;
HOLLT, V .
ACTA NEUROPATHOLOGICA, 1991, 82 (06) :516-519
[6]   Active targeting of brain tumors using nanocarriers [J].
Beduneau, Arnaud ;
Saulnier, Patrick ;
Benoit, Jean-Pierre .
BIOMATERIALS, 2007, 28 (33) :4947-4967
[7]  
Belotti D, 1996, CLIN CANCER RES, V2, P1843
[8]  
Brandes AA, 1996, J NEURO-ONCOL, V30, P247
[9]   ABCC drug efflux pumps and organic anion uptake transporters in human gliomas and the blood-tumor barrier [J].
Bronger, H ;
König, J ;
Kopplow, K ;
Steiner, HH ;
Ahmadi, R ;
Herold-Mende, C ;
Keppler, D ;
Nies, AT .
CANCER RESEARCH, 2005, 65 (24) :11419-11428
[10]   REQUIREMENT OF VASCULAR INTEGRIN ALPHA(V)BETA(3) FOR ANGIOGENESIS [J].
BROOKS, PC ;
CLARK, RAF ;
CHERESH, DA .
SCIENCE, 1994, 264 (5158) :569-571